Affiliation: University of South Florida
- The evolution and application of toxicity criteriaAndy Trotti
H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
Semin Radiat Oncol 12:1-3. 2002..Just as the revised CTC has provided a new common standard for the grading of acute effects, a similar effort is needed in the late effects area. The creation of a unified late effects system is under active development...
- A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancyAndy Trotti
Radiation Oncology Program, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
Int J Radiat Oncol Biol Phys 58:674-81. 2004..It is hypothesized that infection plays a role in the development of OM. We tested the efficacy of iseganan HCl (iseganan), a synthetic peptide with broad-spectrum antimicrobial activity, for preventing RT-associated OM...
- Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultationYuhchyau Chen
Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 8647, USA
Int J Radiat Oncol Biol Phys 64:1442-51. 2006....
- Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI)A Trotti
Division of Radiation Oncology, and the Biostatistics Core, University of South Florida, James A Haley VA Medical Center, Tampa, USA
Int J Radiat Oncol Biol Phys 42:257-61. 1998..The goal was to create a more complete, yet concise, head and neck site-specific module geared toward patients receiving radiation therapy for head and neck cancer...
- TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology GroupAndy Trotti
H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
Lancet Oncol 8:613-24. 2007....
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentAndy Trotti
H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA
Semin Radiat Oncol 13:176-81. 2003..This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0...
- Toxicity in head and neck cancer: a review of trends and issuesA Trotti
Division of Radiation Oncology, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
Int J Radiat Oncol Biol Phys 47:1-12. 2000..Further research into the assessment and analysis of toxicity is not only crucial to improvements in quality of life (QOL), but perhaps, improved rates of disease control as well...
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyA Trotti
H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
Int J Radiat Oncol Biol Phys 47:13-47. 2000..CTC v. 2.0 represents an improvement in the evaluation and grading of acute toxicity for all modalities...
- Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature reviewAndy Trotti
Radiation Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
Radiother Oncol 66:253-62. 2003..To determine the frequency of mucositis and associated outcomes in patients receiving radiotherapy (RT) for head and neck cancer through a systematic review of recently published literature...
- Patient-reported outcomes and the evolution of adverse event reporting in oncologyAndy Trotti
Division of Radiation Oncology, H Lee Moffitt Cancer Center at University of South Florida, Tampa, FL 33612 9416, USA
J Clin Oncol 25:5121-7. 2007..Therefore, care must be used when developing health outcomes and safety data collection plans...
- Assessment of toxicity in cooperative oncology clinical trials: the long and short of itClement K Gwede
Dept of Interdisciplinary Oncology, University of South Florida and H Lee Moffitt Cancer Center and Research Institute, Tampa, USA
J Oncol Manag 11:15-21. 2002..The potential implications for toxicity data management practices, data quality, patient care management and resource utilization are discussed...
- Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinomaCarole Fakhry
Carole Fakhry, Johns Hopkins Medical Institutions Milton J Dance Jr Head and Neck Center, Baltimore, MD Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA David Rosenthal, Adel El Naggar, Adam S Garden, The University of Texas MD Anderson Cancer Center, Houston, TX Andy Trotti, H Lee Moffitt Cancer Center, Tampa, FL Vilija Avizonis, Intermountain Medical Center, Murray, UT Quynh Thu Le, Stanford University Medical Center, Stanford, CA Maura Gillison, Ohio State University Medical Center, Columbus, OH Phuc Felix Nguyen Tan, Denis Soulieres, Centre Hospitalier de l Université de Montréal Hospital Notre Dame, Montreal, Canada
J Clin Oncol 32:3365-73. 2014..Risk of cancer progression is reduced for patients with human papillomavirus (HPV) -positive oropharynx cancer (OPC) relative to HPV-negative OPC, but it is unknown whether risk of death after progression is similarly reduced...
- Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysisTawee Tanvetyanon
Head and Neck Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
Am J Otolaryngol 30:38-43. 2009..Squamous cell carcinoma (SCC) is associated with IP in about 7% of cases. To date, there has been no pooled analysis to formulate a survival outcome associated with this rare condition...
- Skin changesGloria Wood
Radiation Therapy, H Lee Moffitt Cancer Center, Tampa, FL, USA
Cancer Treat Res 128:171-81. 2006..Ongoing research studying acute and late skin effects works to minimize reactions and improve patient quality-of-life. However, research with strong methodology is needed to determine if any management strategy is superior...
- Local excision of T2 and T3 rectal cancers after downstaging chemoradiationC J Kim
Department of Surgery, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
Ann Surg 234:352-8; discussion 358-9. 2001....
- Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14K Kian Ang
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 97, Houston, TX 77030, USA
J Clin Oncol 23:3008-15. 2005..To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC)...
- Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventionsSøren M Bentzen
University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 69:S79-82. 2007
- Complications of radiation therapy for head and neck cancers. The patient's perspectiveAlison M Rose-Ped
Empirica, Inc, Portland, Ore 97225, USA
Cancer Nurs 25:461-7; quiz 468-9. 2002..Trends toward more aggressive management of head and neck cancers underscore the need for new and effective therapies for oropharyngeal mucositis occurring in patients receiving radiotherapy...
- The need for adverse effects reporting standards in oncology clinical trialsAndy Trotti
J Clin Oncol 22:19-22. 2004
- Head and neck cancer: recent advances and new standards of careArlene A Forastiere
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Clin Oncol 24:2603-5. 2006
- Evaluation of new treatments in radiation oncology: are they better than standard treatments?Heloisa P Soares
H Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa 33612, USA
JAMA 293:970-8. 2005..To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention...
- Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy AgencySusan E Davidson
Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
Int J Radiat Oncol Biol Phys 69:1218-21. 2007....
- P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003E Hammond
LDS Hospital, Salt Lake City, UT 84143, USA
Int J Radiat Oncol Biol Phys 57:683-92. 2003..We sought to confirm this finding by analyzing patients entered on RTOG 9003, a Phase III randomized trial of altered fractionation radiotherapy...
- Adverse effects: a Pandora's box for oncologyAndy Trotti
Int J Radiat Oncol Biol Phys 54:642-6. 2002
- Treatment of head and neck cancerAndy Trotti
N Engl J Med 358:1076; author reply 1077-8. 2008
- Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)Adam S Garden
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 71:1351-5. 2008..This article reports the long-term toxicity, relapse patterns, and survival in patients with advanced head and neck carcinoma...
- Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancerArlene A Forastiere
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
N Engl J Med 349:2091-8. 2003..The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown...